Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

BioCentury This Week by BioCentury

Aug 3, 202632:25Science & Medicine

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it. The t...

Related Episodes

Continue listening to more episodes from BioCentury This Week.

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Oct 5, 2026 - 30:09

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis st...

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Sep 30, 2026 - 34:28

Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging...

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Sep 28, 2026 - 37:22

Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropath...

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Sep 21, 2026 - 32:00

The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, tes...

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Sep 14, 2026 - 30:59

Note: This episode was briefly published with an incorrect audio file, which has since been corrected. FD...

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Sep 8, 2026 - 35:05

A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis,...

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Aug 31, 2026 - 35:37

Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals...

Ep. 384 - Back to School Special: The global FIH trials race

Aug 27, 2026 - 42:31

China has changed the global narrative on delivering early human clinical data, with a new bar for speed...